What is GHK-Cu?
GHK-Cu is a copper peptide. The "GHK" part is a tiny chain of three amino acids — glycine, histidine, and lysine — and the "Cu" is a copper ion that the peptide grabs and holds onto, forming a stable copper complex. In cosmetic ingredient lists you will see it written as "copper tripeptide-1." It is the same molecule either way.
GHK is not exotic or synthetic in origin: it occurs naturally in the human body and was first isolated from human plasma in 1973. The body appears to carry less of it as we age — published work puts the plasma level at roughly 200 ng/mL around age 20, declining to about 80 ng/mL by age 60. That age-related drop is the headline behind a lot of the "restore your youth" marketing. It is worth being clear-eyed about it, though: having less of something with age does not, by itself, prove that adding more back produces a benefit. That is a question only controlled human trials can answer.
In the lab and in animals, GHK-Cu has been linked to wound healing, collagen and elastin production, blood-vessel growth, and anti-inflammatory and antioxidant activity. Those are genuine, repeatedly reported findings. The important caveat — which the rest of this page is built around — is that "interesting in a dish and in animals" is a very different claim from "proven to work, at a known dose, in people."
What does GHK-Cu do — the proposed biology?
GHK-Cu is genuinely interesting at the molecular level, and being specific about that is more honest than either hyping it or dismissing it. The most-cited modern work is a wide survey of its effects on gene activity. In laboratory analyses, GHK has been reported to shift the expression of a large number of human genes — reviews describe it as capable of up- or down-regulating on the order of several thousand genes, with one analysis finding it changed expression by at least 50% in roughly a third of the genome it surveyed. That breadth is exactly why it attracts "resets your skin/cells" marketing.
On the building-block side, GHK-Cu is reported to increase synthesis of collagen, elastin, and glycosaminoglycans — the structural and cushioning molecules of skin and connective tissue — and to modulate the metalloproteinase enzymes that remodel that tissue. It has also shown antioxidant and anti-inflammatory activity in cell studies, including reducing inflammatory signalling (such as TNF-α-driven IL-6 release) in fibroblasts. In wound-healing models in animals, it has been linked to faster, better-organised repair.
Here is the crucial framing, though: almost all of this is in vitro (cells in a dish) and animal work. Mapping which genes a molecule touches, or showing it boosts collagen in a fibroblast culture, tells you about plausible mechanisms — it does not prove that applying or injecting GHK-Cu produces a meaningful, safe result in a living person, and it certainly does not establish a dose. A rich mechanism is a reason to run good human trials, not a substitute for them.
Topical vs injected — a crucial difference
This is the single most important thing to understand about GHK-Cu, and it is exactly the thing the phrase "GHK-Cu dosing" tends to hide. There are two completely different ways people use this peptide, and they are not interchangeable.
The first is TOPICAL: GHK-Cu has been an ingredient in creams, serums, and eye treatments for decades. Here it is regulated as a cosmetic ingredient, not as a drug, and it is sold openly in ordinary skincare. A "dose" in this world simply means the concentration in the product and how much you smooth onto your skin — there is no needle involved.
The second is INJECTED or otherwise SYSTEMIC: taking GHK-Cu as a subcutaneous injection, usually sold as a "research peptide," with the goal of body-wide anti-aging or healing effects. This is an entirely different proposition. It is not an FDA-approved medicine, there is no established human dose, and — as the next sections explain — the evidence to support it in humans essentially does not exist. The topical track being legitimate and widely available does not make the injectable track validated. They are two separate stories, and the honest answer to "how do I dose GHK-Cu?" depends entirely on which one you mean.
Is there an official GHK-Cu dose?
For the topical cosmetic version, "dose" is loosely defined the way it is for any skincare ingredient: a copper-peptide serum lists its concentration, and you apply it as directed — typically a thin layer once or twice a day. There is no medical dosing standard because it is a cosmetic, not a prescribed drug. The right amount is whatever the product instructs and what a dermatologist or skincare professional suggests for your skin.
For an injectable or systemic GHK-Cu "dose," there simply is no official answer. The FDA has not approved GHK-Cu as an injectable drug for any indication, which means there is no approved dose, no approved frequency, and no approved route. There is also no published human pharmacokinetic study telling us how injected GHK-Cu is absorbed, distributed, or cleared, and no human dose-ranging trial establishing a minimum effective or maximum safe amount.
So when you see a specific milligram-per-day injection protocol presented online as "the GHK-Cu dose," understand what it actually is: an anecdotal, unvalidated number passed around in hobbyist communities, not a figure that has cleared any clinical or regulatory bar. We are deliberately not reprinting those numbers here, because doing so would dress up guesswork as guidance. There is no validated injectable GHK-Cu dose to give.
What does the evidence actually show?
Here the topical and injected stories diverge sharply, and being precise about the difference is the whole point.
On the TOPICAL side, there is some genuine human data — modest, often small, and frequently industry-associated, but real. The most-cited example is a 12-week study in which a GHK-Cu facial cream applied twice daily to 71 women with photoaged skin was reported to increase skin density and thickness, reduce laxity, improve clarity, and soften fine lines and wrinkle depth, with companion findings for an eye cream. In a laboratory penetration study, copper applied as the tripeptide complex was shown to actually cross human skin in measurable amounts — about 136 micrograms of copper permeated each square centimetre of dermatomed skin over 48 hours, with more retained in the skin as a depot. That matters because crossing the skin barrier is the basic plausibility check any topical has to pass.
But honesty cuts both ways, and the topical evidence is not uniformly glowing. An independent 2006 study published in Archives of Facial Plastic Surgery tested a copper-tripeptide skincare product on patients whose skin had been resurfaced with a CO2 laser and found no significant benefit on the objective measures — no faster resolution of redness, and no significant improvement in wrinkles or overall skin quality versus control — even though patient satisfaction was higher. So the fair summary is mixed-but-real: topical copper peptides have some supporting human data for skin appearance and clearly penetrate the skin, which is why they remain a mainstream cosmetic ingredient, but the results are not large, not consistent, and the endpoint is cosmetic appearance rather than a medical outcome.
On the INJECTED / systemic side, the honest summary is that the human evidence is essentially absent. The bulk of GHK-Cu research is in vitro (cells in a dish) and in animals — wound closure in rodents and pigs, collagen synthesis in fibroblast cultures, and the well-known gene-activity analyses described earlier. That work is biologically intriguing and is what fuels the excitement. But cell and animal results are hypothesis-generating, not proof; they do not establish that injecting GHK-Cu produces a safe, measurable systemic benefit in people. There are no large randomized controlled trials of injected GHK-Cu demonstrating efficacy, a benefit-risk profile, or a dose. The systemic anti-aging and "healing peptide" claims rest on extrapolation from the lab, not on human injectable trials.
| Study / model | Finding | Evidence quality |
|---|---|---|
| Topical facial cream (Pickart & Margolina 2018; 71 women, 12 wk) | Reported higher skin density and thickness, less laxity, and softer fine lines on photoaged skin. | Small human cosmetic (industry-associated) |
| Skin penetration, in vitro (Hostynek 2011) | ~136 µg/cm² of copper from the tripeptide permeated dermatomed human skin over 48 h. | In vitro penetration |
| Gene & tissue mechanism (Pickart 2008; Pickart & Margolina 2015) | Increased collagen, elastin and glycosaminoglycan synthesis and broad gene modulation in cells and animals. | In vitro + animal (mechanism) |
| CO2-laser-resurfaced skin (Miller 2006) | NO significant benefit on erythema, wrinkles or overall skin quality vs control (only patient satisfaction higher). | Controlled human — negative |
| Injected / systemic GHK-Cu | No published human pharmacokinetics, no dose-ranging or efficacy trial; systemic claims are extrapolated from the lab. | No human injectable evidence |
Risks, and why injectable research-grade is an unknown
The topical and injectable routes carry very different risk pictures, too. Topically, copper peptides are generally well tolerated in cosmetic use, with the usual skincare caveats — possible irritation or sensitivity, and the sensible practice of patch-testing a new product. That is a low-stakes, reversible kind of risk.
An injectable, systemic GHK-Cu is a different category of unknown, for two stacked reasons. The first is the molecule: there is no human safety data for injecting GHK-Cu over weeks or months, no established safe dose, and unanswered theoretical questions about what body-wide, pro-growth, pro-angiogenic signaling could do over time. The second is the product itself. GHK-Cu sold for injection is typically labeled "research use only" and "not for human consumption," which means it sits outside the regulated pharmaceutical supply chain. Its identity, purity, copper content, sterility, and actual concentration are not verified to pharmaceutical standards — so even setting aside what the peptide might do, what is physically in the vial is uncertain. An unverified injectable from an unregulated source is a risk that exists independently of any debate about the peptide's biology.
There is also the copper itself to consider. Copper is an essential trace mineral, but it is one the body keeps under tight control, because too much of it is harmful — chronic copper overload can damage the liver and other organs. On the skin, in a cream, the copper carried by a tripeptide is a non-issue. Repeatedly injecting a copper-carrying compound into the body is a different proposition, and there is no human data establishing what dose or frequency would keep copper balance in a safe range. That is one more specific unknown that a topical product simply does not raise, and it is a reason the "just inject it" leap deserves real caution rather than enthusiasm.
Who to ask
If your interest is skin and appearance, the right person to ask is a board-certified dermatologist or a qualified skincare professional. They can tell you whether a topical copper-peptide product makes sense alongside the ingredients that have the strongest evidence, and how to fit it into a routine without irritating your skin.
If you are considering anything injectable or systemic, that is a medical decision, not a skincare one, and it belongs with a licensed physician who can weigh your individual health, review what is actually known and not known, and monitor you. No article — including this one — can stand in for that conversation. PeptidePanel does not sell, source, supply, prescribe, or endorse any compound, and nothing here is medical advice.
Tracking a clinician-guided protocol on PeptidePanel
If a clinician is overseeing a plan that includes GHK-Cu — topical or otherwise — keeping an organized record is genuinely useful, and that is the only role PeptidePanel plays. It is the neutral notebook: logging what you applied or were given and when, tracking any skin assessments or biomarkers your clinician chooses to follow, and keeping a timestamped history you can bring to follow-up visits.
The tool does not recommend a compound, a dose, or a source — those decisions stay entirely between you and your clinician. PeptidePanel simply keeps the record tidy so the people actually making the decisions have a clear picture to work from.